These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31168745)

  • 1. Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
    Hirt C; Iannazzo S; Chiroli S; McGarry LJ; le Coutre P; Stenke L; Dahlén T; Lipton JH
    Appl Health Econ Health Policy; 2019 Aug; 17(4):555-567. PubMed ID: 31168745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    Garcia Molina A
    Farm Hosp; 2024; 48(5):222-229. PubMed ID: 38679535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach.
    García Molina A
    Farm Hosp; 2024; 48(5):T222-T229. PubMed ID: 39013681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
    Levy MY; McGarry LJ; Huang H; Lustgarten S; Chiroli S; Iannazzo S
    Curr Med Res Opin; 2019 Mar; 35(3):479-487. PubMed ID: 30086654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
    Yue X; Hincapie AL; Li Y; Guo JJ
    Leuk Lymphoma; 2022 Apr; 63(4):946-954. PubMed ID: 34775888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
    Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
    Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
    Haddad FG; Issa GC; Jabbour E; Yilmaz M
    Expert Opin Pharmacother; 2022 May; 23(7):751-758. PubMed ID: 35412404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Kawano N; Kimura S; Miura M; Tochigi T; Nakaike T; Yamashita K; Mashiba K; Kikuchi I; Takahashi N
    Int J Hematol; 2021 Oct; 114(4):509-516. PubMed ID: 34406581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV; Larson RA; Dusetzina SB; Apperley JF; Hehlmann R; Baccarani M; Eigendorff E; Guilhot J; Guilhot F; Hehlmann R; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Saussele S; Schiffer CA; Silver RT; Simonsson B; Conti RM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
    Breccia M; Abruzzese E; Castagnetti F; Bonifacio M; Gangemi D; Sorà F; Iurlo A; Luciano L; Gozzini A; Gentile M; Bocchia M; Luzi D; Maggi A; Sgherza N; Isidori A; Crugnola M; Pregno P; Scortechini AR; Capodanno I; Pizzuti M; Foà R
    Ann Hematol; 2018 Sep; 97(9):1577-1580. PubMed ID: 29675611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
    Muresan B; Mamolo C; Cappelleri JC; Postma MJ; Heeg B
    Appl Health Econ Health Policy; 2021 Nov; 19(6):929-940. PubMed ID: 34250585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
    Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
    Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of chronic-phase chronic myeloid leukemia beyond first-line therapy.
    Khoury HJ; Bixby DL
    Leuk Lymphoma; 2015 Mar; 56(3):568-76. PubMed ID: 24884315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.
    Rochau U; Kluibenschaedl M; Stenehjem D; Kuan-Ling K; Radich J; Oderda G; Brixner D; Siebert U
    Leuk Res Treatment; 2015; 2015():982395. PubMed ID: 26783469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.
    Zulbaran-Rojas A; Lin HK; Shi Q; Williams LA; George B; Garcia-Manero G; Jabbour E; O'Brien S; Ravandi F; Wierda W; Estrov Z; Borthakur G; Kadia T; Cleeland C; Cortes JE; Kantarjian H
    Cancer Med; 2018 Nov; 7(11):5457-5469. PubMed ID: 30318751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia.
    Agrawal R; Vieira J; Ryan J; Negi H; Rajput T; Corbin R; Viana R
    Pharmacoeconomics; 2022 Dec; 40(12):1159-1186. PubMed ID: 36175789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.